Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Taxanes are an established option in the standard treatment paradigm for patients with metastatic breast cancer (MBC). Neuropathy is a common, dose-limiting side effect of taxane therapy that is often managed by dose reductions and delays. The severity, time to onset, and improvement in neuropathy are important considerations for patient management and vary among currently approved taxanes. The rate of grade ≥3 neuropathy with taxanes has been shown to be dose and schedule dependent; however, time to improvement to grade ≤1 is typically shorter for nab-paclitaxel than for other taxanes in patients with MBC. Many tools for assessing patient-reported neuropathy exist. Because MBC is incurable and patient quality of life must be critically considered when making treatment decisions, there is a need for more prospective trials to assess patient-reported neuropathy. Validated predictors of taxane-related neuropathy may play an important role in treatment decisions in the future. This review will focus on the toxicity profile (i.e., neuropathy) of each of the taxanes used in the treatment of MBC, will provide updates on tools used for the assessment of neuropathy, and will highlight newly discovered predictors of taxane-related neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other common symptoms among cancer patients (e.g., nausea, neuropathy, swelling of arms and legs, hot flashes, cognitive problems) have received less attention in the MBC literature [6, 12–14].”
From Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility (2017) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 1×
“[85] Metastatic or locally advanced, previously treated (346) Paclitaxel 90 mg/m(2) weekly for 3 of 4 weeks NR 17 <1”
BackgroundGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 1×
“[17] Metastatic, previously treated (229) nab-Paclitaxel 260 mg/m(2) q3w NR 10 0”
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897 · cited 1×
“[84] Metastatic or locally advanced, previously treated (231) Docetaxel 100 mg/m(2) q3w NR 2 (grade 3 or higher)”
BackgroundAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756 · cited 1×
“With respect to taxane-based therapy, in an exploratory analysis of a phase III trial in patients with advanced non-small cell lung cancer, those with diabetes who were treated with nab-paclitaxel plus carboplatin had a 4 % higher rate of grade ≥3 peripheral neuropathy (7 %) than did the intent-to-treat population (3…”
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594 · cited 2×
“[29] Metastatic, previously treated (225) Paclitaxel 175 mg/m(2) q3w 21 12 0”
BackgroundPharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Postma, T. J., Aaronson, N. K., Heimans, J. J., Muller, M. J., Hildebrand, J. G., Delattre, J. Y., Hoang-Xuan, K., Lantéri-Minet, M., Grant, R., Huddart, R., et al. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.02.012 · Cited by 583
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547 · cited 1×
“0001), and a numerically higher ORR (32 vs 25 %; P = NS) versus paclitaxel [33].”
BackgroundPeripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472 · cited 1×
“It is believed that the inhibition of microtubule function affects the structure and function of neurons, resulting in clinically apparent neuropathy [10].”
BackgroundAlbain, K. S., Nag, S. M., Calderillo-Ruiz, G., Jordaan, J. P., Llombart, A. C., Pluzanska, A., Rolski, J., Melemed, A. S., Reyes-Vidal, J. M., Sekhon, J. S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9362 · Cited by 425 · cited 1×
“[81] Metastatic, previously treated (521) Paclitaxel 175 mg/m(2) q3w 18 4–5 <1”
Diagnosis, Management, and Evaluation of Chemotherapy-Induced Peripheral Neuropathy
Hausheer, F. H., Schilsky, R. L., Bain, S., Berghorn, E. J., & Lieberman, F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.010 · Cited by 408
Calhoun, E. A., Welshman, E. E., Chang, C.-H., Lurain, J. R., Fishman, D. A., Hunt, T. L., & Cella, D. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13603.x · Cited by 392
Socinski, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 379 · cited 1×
“As an example, in a phase III trial of patients with advanced non-small cell lung cancer, those receiving firstline paclitaxel plus carboplatin demonstrated increased rates of peripheral neuropathy from cycle 4 (20 %) to cycle 8 (43 %) [21]; the most common reason for not progressing to second-line therapy was residua…”
MethodRao, R. D., Michalak, J. C., Sloan, J. A., Loprinzi, C. L., Soori, G. S., Nikcevich, D. A., Warner, D. O., Novotny, P., Kutteh, L. A., Wong, G. Y., et al. (2007) · Cancer · doi:10.1002/cncr.23008 · Cited by 360
Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5397 · Cited by 341 · cited 2×
“001 overall); independently assessed ORR was also higher with the nab-paclitaxel 100 mg/m(2) qw 3/4, 150 mg/ m(2) qw 3/4, and 300 mg/m(2) q3w arms versus the docetaxel arm (34, 36, and 28 % vs 26 %; P = NS) [27].”
BackgroundMethodPeripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives
Scripture, C., Figg, W., & Sparreboom, A. (2006) · Current Neuropharmacology · doi:10.2174/157015906776359568 · Cited by 320 · cited 1×
“Several of these interventions have been covered in previous reviews of taxane-related neuropathy [12, 57].”
BackgroundAndersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., Sørensen, P. G., Møller, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8213 · Cited by 294 · cited 1×
“[82] Metastatic or locally advanced, previously treated (139) Docetaxel 100 mg/m(2) q3w 19 31 0”
BackgroundCella, D., Peterman, A., Hudgens, S., Webster, K., & Socinski, M. A. (2003) · Cancer · doi:10.1002/cncr.11578 · Cited by 286 · cited 1×
“Numerous patient-reported tools have been validated [75]; however, the Functional Assessment of Cancer Therapy (FACT)Taxane tool is the only taxane-specific tool for assessing patient-reported taxane-related symptoms, including neuropathy [76].”
MethodCavaletti, G., Frigeni, B., Lanzani, F., Mattavelli, L., Susani, E., Alberti, P., Cortinovis, D., & Bidoli, P. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.12.008 · Cited by 274 · cited 3×
“The QLQ-CIPN20 recently demonstrated good validity and reliability scores in a standardization study performed by the Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Study Group, and further studies are planned to evaluate the responsiveness aspects of this tool [73].”
BackgroundMethodWiner, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270 · cited 3×
“[30] Metastatic, previously treated (158) Paclitaxel 175 mg/m(2) q3w 57 (grades 1–4); 7 (grade 3 or higher)”
BackgroundInfluentialChemotherapy-Induced Peripheral Neuropathy: Prevention and Treatment
Pachman, D. R., Barton, D. L., Watson, J. C., & Loprinzi, C. L. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.115 · Cited by 268 · cited 2×
“The degree of neuronal damage depends on several factors, such as agent, cumulative dose, and duration of therapy [6].”
BackgroundHershman, D. L., Weimer, L. H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., Awad, D., & Crew, K. D. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1278-0 · Cited by 264 · cited 1×
“In a second study of patients who were 6 months to 2 years post-adjuvant taxane therapy, 81 % of patients evaluated still reported symptoms of peripheral neuropathy, with up to 27 % reporting severe symptoms in the hands and feet [23].”
BackgroundBarton, D. L., Wos, E. J., Qin, R., Mattar, B. I., Green, N. B., Lanier, K. S., Bearden, J. D., Kugler, J. W., Hoff, K. L., Reddy, P. S., et al. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-010-0911-0 · Cited by 255 · cited 1×
“[91] 208 Phase III, randomized, double-blind study; BAK demonstrated a nonsignificant improvement in symptoms of sensory neuropathy and a significant improvement in motor neuropathy versus placebo (P = .”
BackgroundValero, V., Forbes, J., Pegram, M. D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6450 · Cited by 255
Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer
Perez, E. A., Vogel, C. L., Irwin, D. H., Kirshner, J. J., & Patel, R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4216 · Cited by 250 · cited 1×
“In one study of weekly paclitaxel 80 mg/ m(2) in patients with MBC who received ≤2 prior chemotherapy regimens for metastatic disease, 69 % of patients developed neuropathy and 9 % of patients developed grade 3 neuropathy (no grade 4) [36].”
BackgroundPeripheral nerve damage associated with administration of taxanes in patients with cancer
Argyriou, A. A., Koltzenburg, M., Polychronopoulos, P., Papapetropoulos, S., & Kalofonos, H. P. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.008 · Cited by 240
HUANG, H. Q., BRADY, M. F., CELLA, D., & FLEMING, G. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.00794.x · Cited by 209 · cited 3×
“FACT/GOG-Ntx subscale [73, 74, 77, 92] 11-Item neurotoxicity subscale of FACT-General”
MethodRowinsky, E. K., Chaudhry, V., Cornblath, D. R., & Donehower, R. C. (1993) · PubMed · Cited by 208
Baldwin, R. M., Owzar, K., Zembutsu, H., Chhibber, A., Kubo, M., Jiang, C., Watson, D., Eclov, R. J., Mefford, J., McLeod, H. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1590 · Cited by 204 · cited 1×
“Another genome-wide association study in the CALGB 40101 trial showed a SNP in the gene FGD4 that was associated with the early onset of peripheral neuropathy in patients treated with paclitaxel [40].”
Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing
Forsyth, P. A., Balmaceda, C., Peterson, K., Seidman, A. D., Brasher, P., & Deangelis, L. M. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005805907311 · Cited by 199 · cited 1×
“of paclitaxel 200–250 mg/m(2) q3w in previously treated patients with MBC, follow-up data were obtained in 19 % of patients; peripheral neuropathy had improved or resolved in all of these patients 1–6 months after treatment stopped [37].”
MethodGrothey, A., Nikcevich, D. A., Sloan, J. A., Kugler, J. W., Silberstein, P. T., Dentchev, T., Wender, D. B., Novotny, P. J., Chitaley, U., Alberts, S. R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.5911 · Cited by 198 · cited 1×
“[89] 102 Phase III, randomized, double-blind study; calcium and magnesium significantly decreased the incidence of grade ≥2 sensory neuropathy versus placebo (P = .”
BackgroundRao, R. D., Flynn, P. J., Sloan, J. A., Wong, G. Y., Novotny, P., Johnson, D. B., Gross, H. M., Renno, S. I., Nashawaty, M., & Loprinzi, C. L. (2008) · Cancer · doi:10.1002/cncr.23482 · Cited by 193 · cited 1×
“[53] 125 Phase III, randomized, double-blind study; no benefit of lamotrigine versus placebo”
BackgroundShimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., Ohsumi, S., Makino, H., Mukai, H., Katsumata, N., et al. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0613-7 · Cited by 193 · cited 3×
“Patient Neurotoxicity Questionnaire [70] 2 Subjective items that assess sensory and motor neuropathy”
BackgroundMethodInfluentialToxic neuropathy in patients with pre-existing neuropathy
Chaudhry, V., Chaudhry, M., Crawford, T. O., Simmons-O’Brien, E., & Griffin, J. W. (2003) · Neurology · doi:10.1212/01.wnl.0000043691.53710.53 · Cited by 173 · cited 1×
“While data are limited, some reports have suggested an increased risk of chemotherapy-related peripheral neuropathy or a worsening of preexisting neuropathy in patients with diabetes [47, 48].”
BackgroundKottschade, L. A., Sloan, J. A., Mazurczak, M. A., Johnson, D. B., Murphy, B. P., Rowland, K. M., Smith, D. A., Berg, A. R., Stella, P. J., & Loprinzi, C. L. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-010-1018-3 · Cited by 173
Mao-Ying, Q.-L., Kavelaars, A., Krukowski, K., Huo, X.-J., Zhou, W., Price, T. J., Cleeland, C., & Heijnen, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100701 · Cited by 172 · cited 1×
“A recent preclinical study demonstrated that coadministration of metformin protected mice against chemotherapy-induced peripheral neuropathy [60].”
BackgroundDescription of a short-term Taxol®-induced nociceptive neuropathy in rats
Authier, N., Gillet, J.-P., Fialip, J., Eschalier, A., & Coudore, F. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02910-3 · Cited by 171
Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., Hashemzade, S., Asghari Jafarabadi, M., Montazeri, V., Keshavarz, S. A., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-355 · Cited by 171 · cited 2×
“[59] 69 Randomized, double-blind study; significantly decreased incidence of peripheral neuropathy with omega-3 fatty acid pearls (P = .”
BackgroundAssociation of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Sissung, T. M., Mross, K., Steinberg, S. M., Behringer, D., Figg, W. D., Sparreboom, A., & Mielke, S. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.017 · Cited by 170
Cortés, J., & Saura, C. (2010) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(10)70002-1 · Cited by 161 · cited 1×
“, the median time to improvement in grade 3 neuropathy to grade ≤2 was 22 days for nab-paclitaxel and 79 days for paclitaxel [18].”
BackgroundTabernero, J. M., Climent, M. A., Lluch, A. M., Albanell, J., Vermorken, J. B., Barnadas, A., Anton, A., Laurent, C., Mayordomo, J. I., Estaun, N., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh349 · Cited by 156
Speck, R. M., Sammel, M. D., Farrar, J. T., Hennessy, S., Mao, J. J., Stineman, M. G., & DeMichele, A. (2013) · Journal of Oncology Practice · doi:10.1200/jop.2012.000863 · Cited by 147
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
Swain, S. M., & Arezzo, J. C. (2008) · PubMed · Cited by 142
Mechanism of taxane neurotoxicity
Hagiwara, H., & Sunada, Y. (2004) · Breast Cancer · doi:10.1007/bf02968008 · Cited by 139
Tofthagen, C., McMillan, S. C., & Kip, K. E. (2011) · Cancer Nursing · doi:10.1097/ncc.0b013e31820251de · Cited by 120 · cited 2×
“Chemotherapy-Induced Peripheral Neuropathy Tool [79] 50-Item self-report questionnaire”
BackgroundMethodGradishar, W. J., Krasnojon, D., Валентинович, Ч. С., Makhson, A. N., Manikhas, G., Clawson, A., Bhar, P., McGuire, J. R., & Iglesias, J. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2012.05.001 · Cited by 119
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel
Hertz, D. L., Roy, S., Motsinger‐Reif, A. A., Drobish, A. A., Clark, L. S., McLeod, H. L., Carey, L., & Dees, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt018 · Cited by 116
Grothey, A., Hart, L. L., Rowland, K. M., Ansari, R., Alberts, S. R., Chowhan, N. M., Shpilsky, A., & Hochster, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4010 · Cited by 114 · cited 1×
“038); this trial was terminated early because of a decreased response rate in the calcium and magnesium arm of the CONcePT study, which was also terminated early [90]”
BackgroundReyes-Gibby, C. C., Morrow, P. K., Buzdar, A., & Shete, S. (2009) · The Journal of Pain · doi:10.1016/j.jpain.2009.04.006 · Cited by 114 · cited 1×
“A survey of patients who had previously received paclitaxel treatment for breast cancer revealed that 27 % of those who developed paclitaxel-related neuropathy eventually developed neuropathic pain [24].”
BackgroundGriffith, K. A., Merkies, I. S. J., Hill, E., & Cornblath, D. R. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00292.x · Cited by 110
Marineo, G., Iorno, V., Gandini, C., Moschini, V., & Smith, T. J. (2011) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2011.03.015 · Cited by 109
Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms.
Kautio, A.-L., Haanpää, M. L., Leminen, A., Kalso, E. A., Kautiainen, H., & Saarto, T. H. (2009) · PubMed · Cited by 106
Potential neurotoxicity of the solvent vehicle for cyclosporine.
Windebank, A. J., Blexrud, M. D., & de Groen, P. C. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38962-7 · Cited by 105 · cited 1×
“With respect to neurotoxicity, in preclinical studies, axonal swelling, degeneration, and demyelination have been observed with Cremophor EL [13, 14].”
BackgroundAcupuncture for Chemotherapy-Induced Peripheral Neuropathy (Cipn): A Pilot Study Using Neurography
Schröder, S., Meyer‐Hamme, G., & Epplée, S. (2011) · Acupuncture in Medicine · doi:10.1136/acupmed-2011-010034 · Cited by 104
Schneider, B. P., Zhao, F., Wang, M., Stearns, V., Martino, S., Jones, V. E., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8446 · Cited by 100 · cited 2×
“In an analysis of the ECOG 1199 study of patients with breast cancer who received adjuvant taxane-containing therapy, hyperglycemia and obesity were associated with an increased risk of neuropathy, and African-American race demonstrated a trend toward an increased risk of neuropathy with weekly paclitaxel [44].”
BackgroundMethodRivera, E., Mejia, J. A., Arun, B., Adinin, R. B., Walters, R. S., Brewster, A. M., Broglio, K. R., Yin, G., Esmaeli, B., Hortobágyi, G. N., et al. (2008) · Cancer · doi:10.1002/cncr.23321 · Cited by 99
Self-citationEvaluation of Acupuncture in the Management of Chemotherapy-Induced Peripheral Neuropathy
Donald, G., Tobin, I., & Stringer, J. (2011) · Acupuncture in Medicine · doi:10.1136/acupmed.2011.010025 · Cited by 98
Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
Wozniak, K. M., Nomoto, K., Lapidus, R. G., Wu, Y., Carozzi, V., Cavaletti, G., Hayakawa, K., Hosokawa, S., Towle, M. J., Littlefield, B. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4184 · Cited by 94 · cited 1×
“In a preclinical study, mice treated with ixabepilone or paclitaxel had significant deficits in nerve conduction parameters as well as degenerative changes in the pathology of dorsal root ganglia and sciatic nerves, whereas mice treated with eribulin mesylate did not experience significant effects on nerve conduction…”
BackgroundFountzilas, G., Dafni, U. G., Dimopoulos, M. A., Koutras, A. K., Skarlos, D. V., Papakostas, P., Gogas, H. J., Bafaloukos, D. I., Kalogera‐Fountzila, A., Samantas, E., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0047-9 · Cited by 87
Mir, O., Alexandre, J., Tran, A., Durand, J.-P., Pons, G., Tréluyer, J., & Goldwasser, F. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn698 · Cited by 83 · cited 1×
“An association between a GSTP1 polymorphism and docetaxel-induced peripheral neuropathy has also been identified [42].”
BackgroundPatient-Reported Outcomes in Breast Oncology: A Review of Validated Outcome Instruments
Kanatas, A. N., Velikova, G., Roe, B. H., Horgan, K. J., Ghazali, N., Shaw, R., & Rogers, S. N. (2012) · Tumori Journal · doi:10.1177/030089161209800602 · Cited by 68 · cited 1×
“Numerous patient-reported tools have been validated [75]; however, the Functional Assessment of Cancer Therapy (FACT)Taxane tool is the only taxane-specific tool for assessing patient-reported taxane-related symptoms, including neuropathy [76].”
MethodCallizot, N., Andriambeloson, E., Glass, J. D., Revel, M., Ferro, P., Cirillo, R., Vitte, P., & Dréano, M. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0689-7 · Cited by 63 · cited 1×
“A separate preclinical study demonstrated that concurrent administration of interleukin-6 and cisplatin, vincristine, or paclitaxel in rodents prevented electrophysical abnormalities associated with neuropathy as well as pathological changes in peripheral nerves [61].”
BackgroundRugo, H. S., Barry, W. T., Moreno‐Aspitia, A., Lyss, A. P., Cirrincione, C., Mayer, E. L., Naughton, M., Layman, R. M., Carey, L., Somer, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.cra1002 · Cited by 62
Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation
Osmani, K., Vignes, S., Aissi, M., Wade, F. M., Milani, P., Levy, B. I., & Kubis, N. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6442-5 · Cited by 59 · cited 1×
“One study in patients who were 1–13 years post-taxane therapy demonstrated that paclitaxel- and docetaxel-related peripheral neuropathy completely resolved in only 14 % after treatment discontinuation [22].”
BackgroundKuroi, K., Shimozuma, K., Ohashi, Y., Hisamatsu, K., Masuda, N., Takeuchi, A., Aranishi, T., Morita, S., Ohsumi, S., & Hausheer, F. H. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0550-x · Cited by 55 · cited 1×
“, National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE)], and these scales often have suboptimal reliability, sensitivity, and validity [71, 73, 74].”
Backgroundde Afonseca, S. O., Cruz, F. M., Cubero, D. D. I. G., Lera, A. T., Schindler, F., Okawara, M., de Souza, L. F., Rodrigues, N. P., & del Giglio, A. (2013) · Sao Paulo Medical Journal · doi:10.1590/s1516-31802013000100006 · Cited by 47
Acupuncture Treatment for Bortezomib-Induced Peripheral Neuropathy: A Case Report
Bao, T., Zhang, R.-X., Badros, A. Z., & Lao, L. (2011) · Pain Research and Treatment · doi:10.1155/2011/920807 · Cited by 45
Cunningham, J. E., Kelechi, T. J., Sterba, K. R., Barthelemy, N., Falkowski, P. G., & Chin, S. H. (2011) · Supportive Care in Cancer · doi:10.1007/s00520-011-1231-8 · Cited by 45 · cited 1×
“, massage) completely resolved the patient’s neuropathic symptoms [62].”
BackgroundXu, W.-R., Hua, B., Hou, W., & Bao, Y.-J. (2010) · PubMed · Cited by 44
Schneider, B. P., Li, L., Miller, K. D., Flockhart, D. A., Radovich, M., Hancock, B. A., Kassem, N., Foroud, T., Koller, D. L., Badve, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.1000 · Cited by 44
Rugo, H. S., Barry, W. T., Moreno‐Aspitia, A., Lyss, A. P., Cirrincione, C., Mayer, E. L., Naughton, M., Layman, R. M., Carey, L., Somer, R. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.18_suppl.cra1002 · Cited by 43 · cited 1×
“Rates of neuropathy associated with taxanes or ixabepilone plus bevacizumab for the treatment of MBC from a large cooperative group trial were reported [34].”
BackgroundKuroi, K., Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Ohsumi, S., Watanabe, T., Bain, S., & Hausheer, F. H. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn100 · Cited by 40
Cella, D. F., Huang, H. Q., Homesley, H. D., MONTAG, A. G., Salani, R., Geest, K. D., Lee, R., & Spirtos, N. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.08.022 · Cited by 38
Introduction to organic and biochemistry
Brown, W. H. (1976) · Andalas University Repository (Andalas University) · Cited by 35
Schröder, C. P., de Munck, L., Westermann, A. M., Smit, W. M., Creemers, G., de Graaf, H., Stouthard, J. M., van Deijk, G., Erjavec, Z., van Bochove, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.018 · Cited by 33
Seidman, A. D., Conlin, A. K., Bach, A. M., Moynahan, M. E., Lake, D. E., Forero, A., Wright, G. S., Hackney, M. H., Clawson, A., Norton, L., et al. (2013) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.02.008 · Cited by 32 · cited 1×
“Similarly, in a phase II study of three different doses/schedules of nab-paclitaxel (260 mg/m(2) q3w, 260 mg/m(2) q2w with filgrastim, or 130 mg/m(2) qw) with bevacizumab (10 mg/ kg q2w or 15 mg/kg q3w) in patients with MBC, the ORRs (primary endpoint) were 45, 41, and 46 %, respectively, and rates of grade ≥3 neuropa…”
BackgroundSabato, A. F., Marineo, G., & Gatti, A. (2006) · PubMed · Cited by 30
Bergmann, T. K., Vach, W., Feddersen, S., Eckhoff, L., Gréen, H., Herrstedt, J., & Brøsen, K. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.707787 · Cited by 28 · cited 1×
“1 3 (± bevacizumab) in the adjuvant setting, a genome-wide association study showed that single nucleotide polymorphisms (SNPs) in two genes—RWDD3 and TECTA—were significantly associated with time to onset of neuropathy (P < 5 × 10−7) [38], but this association could not be confirmed in a recent study of Scandinavian…”
BackgroundPatient-reported outcomes in breast oncology: a review of validated outcome instruments
Kanatas, A. N., Velikova, G., & Roe, B. H. (2012) · Edge Hill University Research Information Repository (Edge Hill University) · doi:10.1700/1217.13489 · Cited by 28
Wozniak, K. M., Wu, Y., Farah, M. H., Littlefield, B. A., Nomoto, K., & Slusher, B. S. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9394-3 · Cited by 27 · cited 1×
“A subsequent preclinical study demonstrated that paclitaxel was associated with additional deleterious effects in mice with preexisting paclitaxel-induced peripheral neuropathy, whereas the neuropathic effect with eribulin in these mice was limited [26].”
BackgroundCurrent Methods for the Assessment and Management of Taxane-Related Neuropathy
Smith, E. (2013) · Clinical journal of oncology nursing · doi:10.1188/13.cjon.s1.22-34 · Cited by 21 · cited 3×
“Motor weakness with taxane therapy generally affects the extremities [12].”
BackgroundIntroduction to Organic and Biochemistry
Slabaugh, S. L. S. A. M. R. (2011) · Cited by 18
Campbell, T. C., Nimunkar, A. J., Retseck, J., Eickhoff, J. C., Bačkonja, M., Cleary, J. F., Kwekkeboom, K. L., & Yen, T. Y. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.9635 · Cited by 16 · cited 1×
“However, Scrambler therapy failed to show any significant difference from sham therapy in pain scores in a recent randomized double-blind study of patients with neuropathic pain [65].”
BackgroundSmith, E., Pang, H., Cirrincione, C., Fleishman, S. B., Paskett, E. D., Fadul, C. E., Knox, C., Shapiro, C. L., Gilman, P. B., & Cancer and Leukemia Group B (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.cra9013 · Cited by 15
Grothey, A. F., Qin, R., Dakhil, S. R., Fehrenbacher, L., Stella, P. J., Atherton, P. J., Seisler, D. K., Qamar, R., Lewis, G., & Loprinzi, C. L. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt201.32 · Cited by 14
Hershman, D. L., Unger, J. M., Crew, K. D., Moinpour, C. M., Minasian, L. M., Hansen, L. K., Lew, D. L., O’Kane, P., Wade, J. L., Wong, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.9018 · Cited by 4 · cited 1×
“[54] 409 Phase III, randomized, double-blind study; nonsignificantly decreased neuropathic symptoms at week 12, but significantly increased symptoms by week 24 versus placebo (P = .”
Background
Research works printed but not linked: 1
- Hirsh V, Owen SP, Ko A, Renschler MF, Socinski MA (2013) nab-Paclitaxel in combination with carboplatin as first-line therapy in diabetic patients with advanced non-small cell lung cancer (NSCLC). In: 15th World conference on lung cancer, poster P1 10-044
Cited by
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
“Chemotherapy with taxanes often leads to neuropathy, which can persist long after treatment ends.(35) Anthracyclines and HER-2–targeted drugs can lead to cardiomyopathy and congestive heart failure.”
BackgroundCancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Seca, A., & Pinto, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010263 · Cited by 686
“Higher doses of nab-paclitaxel can be administered over a shorter infusion time, and consequently, there is an improvement in neuropathy side effects after the therapy discontinuation [57], although peripheral sensory neuropathy occurred more frequently with nab-paclitaxel compared to paclitaxel [55].”
BackgroundMetastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
“anthracycline-resistant MBC cases [131, 132].”
Background
Metadata
- Authors
- Rivera, E., & Cianfrocca, M.
- Affiliations
- Banner MD Anderson Cancer Center (US)
- Corresponding author
- Rivera, Edgardo
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2015-01-18
- Volume
- 75
- Issue
- 4
- Pages
- 659-670
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC4365177
- OpenAlex
- W2061239263
- Cited by
- 159
- References
- 89
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 11 · 2023: 14 · 2022: 19 · 2021: 15 · 2020: 19 · 2019: 7 · 2018: 14 · 2017: 16 · 2016: 14 · 2015: 8
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- taxanes, neuropathy, metastatic breast cancer, nab-paclitaxel, paclitaxel, docetaxel, chemotherapy toxicity, dose-limiting toxicity, patient-reported outcomes, quality of life
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Drug Administration Schedule, Female, Humans, Neoplasm Metastasis, Neuralgia, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.